Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue targets for two of its most anticipated drugs: Mounjaro, a diabetes medication, and Zepbound, a high-profile weight-loss drug. Investors, who had anticipated a robust sales report amid growing demand for […]
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide (branded as Zepbound and Mounjaro) dramatically cuts the risk of developing type 2 diabetes by an astounding 94% in adults suffering from pre-diabetes and obesity or overweight. This significant three-year study not only underscores the drug’s potential […]
In a significant development in the field of obesity treatment, Lilly’s Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal of the American Medical Association (JAMA), the study details how Zepbound injection led to superior mean percent changes in body weight compared to placebo among adults with obesity or overweight, […]
The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Zepbound (tirzepatide) injection, making it the only obesity treatment that activates both GIP and GLP-1 hormone receptors. This medication is tailored for adults with obesity or overweight conditions associated with weight-related medical issues such as hypertension and type 2 diabetes. Zepbound is recommended […]